{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013590","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.215574+00:00","generated_at":"2026-06-12T03:45:57.031387+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Capricor reports Q2 net loss $7.4M; HOPE-3 DMD trial on track for Q4 2023 interim analysis","bullets":["Cash, equivalents & marketable securities $37.8M as of June 30, down from $41.4M Dec 31, 2022.","Q2 revenue $3.9M from Nippon Shinyaku upfront recognition vs. $0 in prior year; operating expenses $11.7M vs $7.3M.","HOPE-3 Phase 3 DMD trial: 48 of ~68 patients randomized across 17 sites; enrollment completion and interim analysis expected Q4 2023.","Held FDA Type-B clinical meeting to discuss CAP-1002 BLA pathway; final minutes awaited.","Raised ~$2.1M net via ATM at avg $4.87/share; cash runway through Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013590","json":"https://secwatch.observer/filing/0001558370-23-013590.json","markdown":"https://secwatch.observer/filing/0001558370-23-013590.md","text":"https://secwatch.observer/filing/0001558370-23-013590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023013590/0001558370-23-013590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023013590/capr-20230807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:45:57.031387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a391f9ddba68c20b130634498d01429be76c880","claim":"CAPRICOR THERAPEUTICS, INC. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the second quarter ended June 30, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023013590/0001558370-23-013590-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}